Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer loses...

    Pfizer loses blockbuster Epilepsy drug patent fight in UK Supreme Court

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-15T11:42:23+05:30  |  Updated On 17 Aug 2021 12:46 PM IST
    The expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut-price versions of Pfizer's medicine, which carried a "skinny label" limiting their use to epilepsy and general anxiety disorder.

    LONDON: Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica.


    The Supreme Court decision is a blow for the U.S. drugmaker which had sought to affirm a secondary medical use patent for the product and a win for generic drug companies Actavis, now renamed Allergan, and Mylan.


    Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.


    In a bid to protect this lucrative section of the market, Pfizer secured a secondary patent, valid beyond the life of the original one.


    The Supreme Court, however, ruled that the secondary patent claims relevant to neuropathic pain were invalid.


    For Pfizer, the legal fight had become a point of principle, following years of battles in lower courts, since its key secondary pain patent has now expired in Europe.


    Pfizer said it was disappointed by the ruling and the decision would have a significant impact on incentives for innovation in public health.


    "The period that a medicine is under patent is a critical phase in its lifecycle that fuels innovation as science evolves and knowledge grows, patients increasingly benefit from ongoing research into new uses for existing medicines," the company said.


    "As situations such as these are expected to become more common, it's important for patients that pharmaceutical companies are able to protect patents, including second medical use patents."


    The expiry of the basic patent on Lyrica five years ago had allowed generic drugmakers to launch cut-price versions of Pfizer's medicine, which carried a "skinny label" limiting their use to epilepsy and general anxiety disorder.


    Pfizer sued, arguing it was inevitable that the copycat versions would be dispensed for pain as well as other conditions.


    The U.S. group took the case to the Supreme Court after an appeal in the case was rejected in 2016. Since then Pfizer's secondary neuropathic pain patent in Britain has also expired, in July 2017.


    In the United States, by contrast, Pfizer is only expecting generic competition to Lyrica in 2019.


    The Supreme Court is the final court of appeal in Britain for civil cases. Pfizer said it was "too early" for it to determine or comment on any possible next steps.


    Read Also: FDA approves Pfizer's Lorbrena treatment for certain lung cancer patients

    AllerganEpilepsygeneral anxiety disorderLyricamedical use patentsMylanneuropathic painPfizerpregabalinpublic healthskinny labelUK Supreme Court
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok